Clinical Study of the Safety and Efficacy of BAT5906 Injection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

November 6, 2023

Study Completion Date

November 6, 2023

Conditions
Diabetic Macular Edema
Interventions
DRUG

2.5mg of BAT5906

Specification: 2.5mg of BAT5906

DRUG

4.0mg of BAT5906

Specification: 4.0mg of BAT5906

Trial Locations (19)

100730

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijiang

Unknown

Eye Hospital of China Academy of Chinese Medical Sciences, Beijing

Peking University First Hospital, Beijing

The First Affiliated Hospital of Bengbu Medical College, Bengbu

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

Zhejiang Provincial People's Hospital, Hangzhou

Henan Provincial Eye Hospital, Henan

Jieyang People's Hospital, Jieyang

The First Hospital of Jilin University, Jilin

The Affiliated Eye Hospital of Nanchang University, Nanchang

Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing

Affiliated Hospital of Nantong University, Nantong

Affiliated Hospital of Qingdao University, Qingdao

Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou

West China Hospital of Sichuan University, Sichuan

Wenzhou Medical University Affiliated Optometry Hospital, Wenzhou

The Second Xiangya Hospital of Central South University, Xiangya

Xiangya Hospital Central South University, Xiangya

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Sponsors
All Listed Sponsors
lead

Bio-Thera Solutions

INDUSTRY